Publicacións nas que colabora con Ricardo Blanco Alonso (22)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  2. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2023

  1. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis

    European Journal of Internal Medicine

  2. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

  3. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

2021

  1. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 299-308

  2. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

2020

  1. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  2. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: Data from the RELESSER Registry

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2043-2051

2019

  1. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 6, pp. 1025-1029

2018

  1. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus

    Arthritis Research and Therapy, Vol. 20, Núm. 1

2017

  1. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 38-45

  2. Juvenile- and adult-onset systemic lupus erythematosus: A comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 6, pp. 1047-1055

2016

  1. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47

  2. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

  3. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 7, pp. 720-729

  2. Cardiovascular events in systemic lupus erythematosus: A Nationwide Study in Spain from the RELESSER Registry

    Medicine (United States), Vol. 94, Núm. 29